Atypical hemolytic uremic syndrome: a rare complication of postendoscopic retrograde cholangiopancreatography pancreatitis. [PDF]
Nanagiri A +4 more
europepmc +1 more source
Real-World effectiveness of eculizumab in atypical hemolytic uremic syndrome: a retrospective study from Western China. [PDF]
Hu Y, Zhang Y, Wang W, Li G, Chen S.
europepmc +1 more source
Ocular Manifestations in Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab: A Case Report and Review of the Literature. [PDF]
Flindris K +6 more
europepmc +1 more source
Clinical and genetic characteristics of patients diagnosed with atypical hemolytic uremic syndrome (aHUS): epidemiological data from the Belgian cohort of the Global aHUS Registry. [PDF]
Massart A +16 more
europepmc +1 more source
Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge. [PDF]
Jiménez Mayor E +7 more
europepmc +1 more source
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy. [PDF]
Java A.
europepmc +1 more source
Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report. [PDF]
Yang H, Zhang J, Wu H, Xu H, Xu Z.
europepmc +1 more source
Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study). [PDF]
Hanna RM +8 more
europepmc +1 more source
Related searches:
Atypical Hemolytic–Uremic Syndrome
New England Journal of Medicine, 2009The hemolytic–uremic syndrome, which is characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal impairment, occurs most frequently in young children. Most cases are secondary to infection with Escherichia coli O157:H7 and other Shiga-toxin–producing strains.
Marina Noris +2 more
exaly +3 more sources
Pathogenesis of Atypical Hemolytic Uremic Syndrome
Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP).
Yoichirô Ikeda, Masaomi Nangaku
exaly +4 more sources

